Publications in collaboration with researchers from Brigham and Women's Hospital (36)

2024

  1. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

    Journal of Cardiac Failure

  2. Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes

    Nature Communications, Vol. 15, Núm. 1

  3. Ischemia Severity, Coronary Artery Disease Extent, and Exercise Capacity in ISCHEMIA

    Circulation, Vol. 150, Núm. 2, pp. 165-167

  4. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

2023

  1. Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries (Nature Genetics, (2023), 55, 1, (89-99), 10.1038/s41588-022-01222-9)

    Nature Genetics

  2. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

    Nature Genetics, Vol. 55, Núm. 1, pp. 89-99

  3. Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology

    European Journal of Heart Failure, Vol. 25, Núm. 4, pp. 457-468

  4. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

    Journal of the American College of Cardiology, Vol. 81, Núm. 1, pp. 34-45

  5. Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial

    JACC: Heart Failure, Vol. 11, Núm. 12, pp. 1729-1738

  6. Spectral power ratio as a measure of EEG changes in mild cognitive impairment due to Alzheimer's disease: a case-control study

    Neurobiology of Aging, Vol. 130, pp. 50-60

2022

  1. Assessment of Omecamtiv Mecarbil for the Treatment of Patients with Severe Heart Failure: A Post Hoc Analysis of Data from the GALACTIC-HF Randomized Clinical Trial

    JAMA Cardiology, Vol. 7, Núm. 1, pp. 26-34

  2. Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial

    European heart journal, Vol. 43, Núm. 2, pp. 148-149

  3. Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry

    ESC Heart Failure, Vol. 9, Núm. 4, pp. 2189-2198

  4. Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF-VAD registry

    European Journal of Heart Failure, Vol. 24, Núm. 7, pp. 1305-1315

  5. Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial

    Journal of the American College of Cardiology, Vol. 79, Núm. 7, pp. 651-661

  6. Review of the current evidence for topical treatment for venous leg ulcers

    Journal of Vascular Surgery: Venous and Lymphatic Disorders, Vol. 10, Núm. 1, pp. 241-247.e15

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Genetic Predisposition to Coronary Artery Disease in Type 2 Diabetes Mellitus

    Circulation: Genomic and Precision Medicine, Vol. 13, Núm. 6, pp. E002769

  2. Initial invasive or conservative strategy for stable coronary disease

    New England Journal of Medicine, Vol. 382, Núm. 15, pp. 1395-1407

  3. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet, Vol. 396, Núm. 10253, pp. 759-769